Iqbal M P, Baig J A, Ali A A, Niazi S K, Mehboobali N, Hussain M A
Department of Biochemistry, Aga Khan University, Karachi, Pakistan.
Biopharm Drug Dispos. 1998 Apr;19(3):163-7. doi: 10.1002/(sici)1099-081x(199804)19:3<163::aid-bdd82>3.0.co;2-l.
We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurrently taking the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, diclofenac, naproxen, indomethacin, and ibuprofen. The area under the curve, the total systemic clearance, the distribution volume, and the half-life of methotrexate in patients receiving concurrent NSAID therapy did not change significantly (at p < 0.05). Concurrent treatment with NSAIDs resulted in increased inter-patient variability of methotrexate concentration, possibly as a result of biochemical interactions; however, it does not appear clinically relevant. The data suggest that the NSAIDs do not significantly affect the disposition of methotrexate, contrary to some of the earlier reports.
我们研究了类风湿性关节炎患者同时服用最常用的非甾体抗炎药（NSAIDs）、阿司匹林、双氯芬酸、萘普生、吲哚美辛和布洛芬时甲氨蝶呤的药代动力学。接受NSAID联合治疗的患者中，甲氨蝶呤的曲线下面积、全身总清除率、分布容积和半衰期没有显著变化（p<0.05）。NSAIDs联合治疗导致甲氨蝶呤浓度的患者间变异性增加，这可能是生化相互作用的结果；然而，这在临床上似乎并无关联。数据表明，与一些早期报告相反，NSAIDs不会显著影响甲氨蝶呤的处置。
